{"id":781319,"date":"2023-08-31T08:32:58","date_gmt":"2023-08-31T12:32:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/"},"modified":"2023-08-31T08:32:58","modified_gmt":"2023-08-31T12:32:58","slug":"aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/","title":{"rendered":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford"},"content":{"rendered":"
\n

\n Samples to be used in validating the Company\u2019s EndoCheck<\/em>
\n
\n SM<\/em>
\n <\/sup>
\n test in development for the diagnosis of endometriosis<\/em>
\n \n <\/p>\n

AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health Inc. (\u201cAspira\u201d or \u201cthe Company\u201d) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company\u2019s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM<\/sup>, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.<\/p>\n

\u201cWe are excited to enter into this agreement with The University of Oxford. With their samples, we will be able to drive our EndoCheck validation process forward and bring this much needed test to market,\u201d said Nicole Sandford, Chief Executive Officer of Aspira. \u201cThere are currently more than six million women suffering from endometriosis in the U.S., with many facing years of pain before getting a diagnosis. We intend to provide clinicians with a highly effective tool to assess the likelihood that a patient\u2019s chronic pain is caused by endometriosis without an invasive procedure. I believe the availability of a simple blood test will support the development and adoption of new therapeutic solutions for this devastating disease, and help patients access treatments sooner than is possible today.\u201d<\/p>\n

Professor Christian Becker, from the Nuffield Department of Women\u2019s and Reproductive Health, University of Oxford and Co-Director of the Oxford Endometriosis Care (EndoCaRe) Centre said, \u201cAn important step towards improving outcomes for women with endometriosis is faster, more reliable diagnosis. We are excited to support Aspira Women\u2019s Health in developing a much-needed test for the identification of this debilitating disease.\u201d<\/p>\n

\n About EndoCheck<\/strong>
\n
\n SM<\/strong>
\n <\/sup>
\n
EndoCheck is a non-invasive blood test in development to be used in conjunction with other non-surgical modalities to aid in the diagnosis of endometriosis and guide in the clinical care for patients with suspected endometriosis earlier in their prognosis journey. Current detection methods for endometriosis require surgery and a surgical biopsy diagnosis and\/or visualization diagnosis. EndoCheck is intended to address this large patient population by using a non-invasive solution with comparable sensitivity and specificity when compared to invasive methods such as surgical biopsy and\/or visualization.<\/p>\n

\n About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0<\/strong>
\n
Aspira Women\u2019s Health Inc. is transforming gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0<\/p>\n

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuiteSM<\/sup>, which includes OvaWatchSM<\/sup>, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus\u00ae<\/sup>\u00a0combines our FDA-cleared products, Ova1\u00ae\u00a0<\/sup>and Overa\u00ae<\/sup>, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.\u00a0\u00a0\u00a0<\/p>\n

EndoCheckSM<\/sup>, Aspira\u2019s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at\u00a0www.aspirawh.com<\/a>.\u00a0\u00a0<\/p>\n

\n Forward-Looking<\/strong>\u00a0Statements<\/strong>
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the potential effects of widespread use of OvaWatch and the availability of OvaWatch in New York. Forward-looking statements involve a number of risks and uncertainties. Words such as \u201cmay,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cpotential,\u201d \u201cprojects\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including those described in the section entitled \u201cRisk Factors\u201d in Aspira\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, and as supplemented in Aspira\u2019s 10-Q filings for the quarters ended March 31, 2023 and June 30, 2023. These risks include, but are not limited to: our ability to continue as a going concern; our ability to comply with Nasdaq\u2019s continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through our Medicare Administrative Carrier for Ova1; impacts resulting from or relating to the COVID-19 pandemic and actions taken to contain it; anticipated use of capital and its effects; our ability to increase the volume of our product sales; failures by third-party payers to reimburse for our products and services or changes to reimbursement rates; our ability to continue developing existing technologies and to develop, protect and promote our proprietary technologies; plans to develop and perform laboratory developed tests; our ability to comply with Food and Drug Administration (\u201cFDA\u201d) regulations that relate to our products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; or our suppliers\u2019 ability to comply with FDA requirements for production, marketing and post-market monitoring of our products; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; in the event that we succeed in commercializing our products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of Aspira Labs; our ability to use our net operating loss carryforwards; our ability to use intellectual property; our ability to successfully defend our proprietary technology against third parties; our ability to obtain licenses in the event a third party successfully asserts proprietary rights; the liquidity and trading volume of our common stock; the concentration of ownership of our common stock; our ability to retain key employees; our ability to secure additional capital on acceptable terms to execute our business plan; business interruptions; the effectiveness and availability of our information systems; our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; future litigation against us, including infringement of intellectual property and product liability exposure; and additional costs that may be required to make further improvements to our laboratory operations. The events and circumstances reflected in Aspira\u2019s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n
\n Investor Relations Contact:<\/em>
\n <\/strong>
\n
Monique Kosse\u00a0
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820
monique@lifesciadvisors.com<\/em><\/strong><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Samples to be used in validating the Company\u2019s EndoCheck SM test in development for the diagnosis of endometriosis AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health Inc. (\u201cAspira\u201d or \u201cthe Company\u201d) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company\u2019s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023. \u201cWe are excited to enter into this agreement with The University of Oxford. With their samples, we … <\/p>\n

Continue reading “Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781319","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Samples to be used in validating the Company\u2019s EndoCheck SM test in development for the diagnosis of endometriosis AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health Inc. (\u201cAspira\u201d or \u201cthe Company\u201d) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company\u2019s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023. \u201cWe are excited to enter into this agreement with The University of Oxford. With their samples, we … Continue reading "Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T12:32:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford\",\"datePublished\":\"2023-08-31T12:32:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/\"},\"wordCount\":1158,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/\",\"name\":\"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==\",\"datePublished\":\"2023-08-31T12:32:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk","og_description":"Samples to be used in validating the Company\u2019s EndoCheck SM test in development for the diagnosis of endometriosis AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health Inc. (\u201cAspira\u201d or \u201cthe Company\u201d) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company\u2019s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023. \u201cWe are excited to enter into this agreement with The University of Oxford. With their samples, we … Continue reading \"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-31T12:32:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford","datePublished":"2023-08-31T12:32:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/"},"wordCount":1158,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/","name":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==","datePublished":"2023-08-31T12:32:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDE0NSM1NzkxOTU4IzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-signs-exclusive-sample-procurement-agreement-with-the-university-of-oxford\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781319"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781319\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}